1. Overview of FDA’s expanded access program for investigational drugs;Jarow;Ther Innov Regul Sci,2017
2. 7. Food and Drug Administration. Expanded Access Program Report. 2018. Available at: www.fda.gov/media/119971/download (accessed October 31, 2020).
3. 13. Food and Drug Administration. IRB review of individual patient expanded access requests for investigational drugs and biological products during the COVID-19 public health emergency. June 2020. Available at: www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-board-irb-review-individual-patient-expanded-access-requests-investigational (accessed October 31, 2020).
4. Alzheimer’s disease drug development pipeline: 2019;Cummings;Alzheimers Dement (N Y),2019
5. Impact of expanded access on FDA regulatory action and product labeling;Jarlow;Ther Innov Regul Sci,2017